Oral famotidine: a potential treatment for children with autism

Famotidine (Pepcid®), a histamine-2 receptor blocker, is marketed for the treatment of peptic ulcer disease, gastroesophageal reflux, and the treatment of pathological hypersecretory conditions, including the Zollinger-Ellison syndrome. Recent reports indicate that it is also effective in relieving...

Full description

Saved in:
Bibliographic Details
Published inMedical hypotheses Vol. 48; no. 5; pp. 381 - 386
Main Author Linday, L.A.
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 01.05.1997
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Famotidine (Pepcid®), a histamine-2 receptor blocker, is marketed for the treatment of peptic ulcer disease, gastroesophageal reflux, and the treatment of pathological hypersecretory conditions, including the Zollinger-Ellison syndrome. Recent reports indicate that it is also effective in relieving the deficit (or withdrawal) symptoms of adults with schizophrenia. Autism, a neuropsychiatric disorder which presents within the first few years of life, is defined by deficient social interaction, communication, language, play, and a markedly restricted repertoire of activities and interests. Similarities between the deficit symptoms of schizophrenia and the social deficit symptoms of autism suggest the hypothesis that famotidine may be useful in treating children with autism. Histamine serves as a neurotransmitter and neuromodulator in the brain. HZ-receptors in the brain predominantly transmit inhibitory signals; when these receptors are stimulated in animals, spontaneous activity and exploratory behavior decrease; blockade of H 2-receptors would therefore be expected to reverse this inhibition.
ISSN:0306-9877
1532-2777
DOI:10.1016/S0306-9877(97)90032-3